GB201702392D0 - Methods for cancer diagnosis using a gene expression signature - Google Patents

Methods for cancer diagnosis using a gene expression signature

Info

Publication number
GB201702392D0
GB201702392D0 GBGB1702392.0A GB201702392A GB201702392D0 GB 201702392 D0 GB201702392 D0 GB 201702392D0 GB 201702392 A GB201702392 A GB 201702392A GB 201702392 D0 GB201702392 D0 GB 201702392D0
Authority
GB
United Kingdom
Prior art keywords
methods
gene expression
cancer diagnosis
expression signature
signature
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1702392.0A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Edinburgh
Original Assignee
University of Edinburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Edinburgh filed Critical University of Edinburgh
Priority to GBGB1702392.0A priority Critical patent/GB201702392D0/en
Publication of GB201702392D0 publication Critical patent/GB201702392D0/en
Priority to PCT/GB2018/050400 priority patent/WO2018150179A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
GBGB1702392.0A 2017-02-14 2017-02-14 Methods for cancer diagnosis using a gene expression signature Ceased GB201702392D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1702392.0A GB201702392D0 (en) 2017-02-14 2017-02-14 Methods for cancer diagnosis using a gene expression signature
PCT/GB2018/050400 WO2018150179A1 (en) 2017-02-14 2018-02-14 Methods for cancer diagnosis using a gene expression signature

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1702392.0A GB201702392D0 (en) 2017-02-14 2017-02-14 Methods for cancer diagnosis using a gene expression signature

Publications (1)

Publication Number Publication Date
GB201702392D0 true GB201702392D0 (en) 2017-03-29

Family

ID=58461937

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1702392.0A Ceased GB201702392D0 (en) 2017-02-14 2017-02-14 Methods for cancer diagnosis using a gene expression signature

Country Status (2)

Country Link
GB (1) GB201702392D0 (en)
WO (1) WO2018150179A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201819125D0 (en) * 2018-11-23 2019-01-09 Univ Oxford Innovation Ltd Biomarkers and uses thereof
WO2021011660A1 (en) * 2019-07-15 2021-01-21 Oncocyte Corporation Methods and compositions for detection and treatment of lung cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT410753B (en) * 2000-11-28 2003-07-25 Biodevelops Verwertung Von Liz PIBF FOR DIAGNOSIS OF TUMORS
AU2002322280A1 (en) * 2001-06-21 2003-01-21 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2003073911A2 (en) * 2002-02-28 2003-09-12 Georgetown University Method and composition for detection and treatment of breast cancer
US7820382B2 (en) * 2004-08-03 2010-10-26 Bauer A Robert Method for the early detection of breast cancer, lung cancer, pancreatic cancer and colon polyps, growths and cancers as well as other gastrointestinal disease conditions and the preoperative and postoperative monitoring of transplanted organs from the donor and in the recipient and their associated conditions related and unrelated to the organ transplantation
MX2012000921A (en) * 2009-07-24 2012-06-12 Geadic Biotec Aie Markers for endometrial cancer.
US10041126B2 (en) * 2012-01-27 2018-08-07 Vib Vzw Monocyte biomarkers for cancer detection

Also Published As

Publication number Publication date
WO2018150179A1 (en) 2018-08-23

Similar Documents

Publication Publication Date Title
SG10201913631TA (en) Rna for cancer therapy
IL251464A0 (en) Combination therapy for cancer
EP3226763A4 (en) Imaging a body
EP3110428A4 (en) A system for tissue manipulation
GB201512869D0 (en) Gene signature for minute therapies
EP3137144A4 (en) A patient interface
EP3193995A4 (en) A patient interface
HK1231559A1 (en) Method for detecting a solid tumor cancer
EP3216007A4 (en) Computer-aided card design validation
HK1231381A1 (en) Combination therapy for cancer
GB201407322D0 (en) Gene therapy
IL246761A0 (en) Combination therapy for cancer
IL249254A0 (en) Gene expression system
GB201908591D0 (en) Methods for cancer diagnosis
GB2552271B (en) A method for diagnosing lung cancer
ZA201608820B (en) Method for treating drug resistant cancer
GB201707212D0 (en) Gene therapy for ciliopathies
GB201702392D0 (en) Methods for cancer diagnosis using a gene expression signature
EP3273974A4 (en) Therapy for malignant disease
EP3134548A4 (en) Cancer prognosis signatures
EP3149483A4 (en) A diagnostic and therapeutic tool for cancer
GB201721746D0 (en) A gene signature for postrate cancer
GB201608907D0 (en) Means for modulating gene expression
GB201622071D0 (en) A gene signature for prostate cancer
GB201712669D0 (en) Touchscreen interaction

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)